MENTARI THERAPEUTICS
LIVE

Serial Number

50072913

Owner

Mentari Therapeutics, Inc.

Attorney

Austin D. Padgett, Esq.

Filing Date

Aug 26, 2026

Add to watchlist:

No watchlists yet
View on USPTO

MENTARI THERAPEUTICS Trademark

Serial Number: 50072913

MENTARI THERAPEUTICS is a trademark filed by Mentari Therapeutics, Inc. on August 26, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Mentari Therapeutics, Inc. (13 trademarks)

221 Crescent Street, Building 23, Suite 105
Waltham, MA 02453

Entity Type: 03

Trademark Details

Filing Date

August 26, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the prevention and treatment of migraine, chronic migraine, episodic migraine, and migraine-associated disorders; biologics for the prevention and treatment of migraine; biopharmaceutical preparations for the prevention and treatment of migraine and migraine-associated disorders; biological preparations for therapeutic use in the prevention and treatment of migraine; bispecific antibodies for therapeutic use, namely for the prevention of migraine; pharmaceutical preparations comprising anti-PACAP antibodies for the prevention and treatment of migraine; pharmaceutical preparations comprising anti-CGRP antibodies for the prevention and treatment of migraine; pharmaceutical preparations comprising bispecific antibodies targeting both CGRP and PACAP for therapeutic use in the prevention of migraine; pharmaceutical preparations for the treatment of neurological disorders; biologic preparations for the treatment of neurological disorders; pharmaceutical preparations for subcutaneous injection for the prevention of migraine; injectable pharmaceutical preparations in the field of migraine prevention; pharmaceutical preparations for self-administration via autoinjector for the prevention of migraine; pharmaceutical preparations for quarterly subcutaneous administration for the prevention of migraine; monospecific antibodies for therapeutic use, namely for the prevention of migraine

Filing History

APPLICATION FILING RECEIPT MAILED
Aug 26, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 26, 2026 NWOS
NEW APPLICATION ENTERED
Aug 26, 2026 NWAP